Business Wire

DE-CIX Launches ‘Project Reach’ with Bandwidth Infrastructure Partner euNetworks

Del

DE-CIX, the world’s leading Internet Exchange operator, today announced the launch of ‘Project Reach’, together with its launching partner euNetworks. Project Reach focuses on DE-CIX’s desire to extend its reach into more data centres, therefore expanding the locations where customers can connect to and access the DE-CIX peering platform. DE-CIX partners with carriers, leveraging their transport networks and points of presence (PoPs) for additional access. In addition to existing DE-CIX enabled sites, where DE-CIX maintains its own hardware, these new access sites are added with partners – such as euNetworks – who maintain and manage the hardware.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180711005276/en/

Brady Rafuse (Photo: Business Wire)

Brady Rafuse (Photo: Business Wire)

“We want to make it easy for peers located in any data centre to connect to our DE-CIX Service World,” said Dr. Thomas King, Chief Innovation Office at DE-CIX. “euNetworks has an impressive network footprint across Germany and Europe. Their focus on connecting to all the key data centres across the region with fibre, combined with their service performance and delivery capability, makes euNetworks an ideal partner as we launch this project. We’re excited to be able to offer our customers an extended ‘one-stop-shop’ solution.”

euNetworks owns and operates deep, fibre based networks in 14 cities across Europe, with 7 of these in Germany. Along with a Pan German backbone, euNetworks’ long haul network spans 49 cities in 15 countries, offering both scalability and diversity across its footprint. euNetworks directly connects to over 350 data centres in its operating markets, with these sites being key to high bandwidth consuming companies.

“We’re excited to be supporting DE-CIX as they seek to extend their geographical reach to customers,” said Brady Rafuse, Chief Executive Officer of euNetworks. “We have a great working relationship with the DE-CIX team and this partnership extends that further, with the euNetworks Customer Ordering Portal and Ethernet services supporting a smooth and rapid service delivery experience to the DE-CIX community.”

euNetworks Carrier Ethernet service to support DE-CIX Project Reach:

  • Plug and play with portal ordering process
  • Layer 2 architecture VPLS/MPLS
  • MEF certified carrier class Ethernet
  • Segmentation of traffic through customer VLANS
  • Backbone protected
  • Customer ports at euNetworks’ connected data centres
  • 10G Ethernet NNI to DE-CIX and dedicated 10G ports

About euNetworks

euNetworks is a bandwidth infrastructure company, owning and operating 14 fibre based metropolitan networks connected with a high capacity intercity backbone covering 49 cities in 15 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 350 today. euNetworks is also a leading cloud connectivity provider, directly connecting 14 cloud platforms with access to a further 7. The company offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs.

For further information visit www.eunetworks.com.

About DE-CIX

DE-CIX provides premium interconnection services and runs a range of carrier and data center-neutral IXs globally. Founded in 1995, DE-CIX serves 1300+ carriers, ISPs and content networks from 100+ countries, including all leading international players in various metro markets in Europe, the Middle East, India and North America.

With 6.4+ Terabits per second of peak traffic, DE-CIX Frankfurt is the world’s leading Internet Exchange. For more information, please visit www.de-cix.net.

Contact information

euNetworks contact:
Hannah Britt
Senior Director, Marketing & IR
hannah.britt@eunetworks.com
+44 20 7952 1338
+44 7717 896 446
or
DE-CIX media contact:
Carsten Titt
Senior Manager Global Public Relations
+49 (0)69 1730902 130
carsten.titt@de-cix.net
www.de-cix.net

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science26.5.2019 07:00:00 CESTPressemelding

Nanopharmaceutics promises ground-breaking innovation in the development of medicines: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/ The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medic

XINHUANET: Promotion Event of The Most Beautiful Shooting Location in China Held During Cannes Film Festival25.5.2019 18:20:00 CESTPressemelding

On May 16 (local time), an event was held at the 72nd Cannes Film Festival to recommend China’s most beautiful shooting locations on the theme of “Fascinating China.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190525005008/en/ The representative from Cannes Convention Bureau (1st L), Michel Chevillon (C), vice president of the French Riviera Chamber of Commerce and Industry and head of hotel association, and Adeline CHAUVEAU (3rd R), officer in charge of film and television projects from French Embassy to China, pose for a group photo with the representatives from the cities awarded for "The most beautiful shooting location in China." (Photo: Business Wire) In the event, the Yellow Sea National Forest Park in Dongtai, Jiangsu Province, the One Hundred Mile Azalea Forest in Bijie, Guizhou Province, Siming District of Xiamen, Fujian Province, and the Li Autonomous County in Lingshui, Hainan Province were on the list. The p

Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 14:00:00 CESTPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo

Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 10:20:00 CESTPressemelding

Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with

New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 05:00:00 CESTPressemelding

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of

The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 01:00:00 CESTPressemelding

For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta